Liu Ru-Tao, Zhang Peng, Yang Chun-Lin, Pang Yu, Zhang Min, Zhang Na, Yue Long-Tao, Li Xiao-Li, Li Heng, Duan Rui-Sheng
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Department of Pathology, Tai'an City Central Hospital, Tai'an 271000, PR China.
J Neuroimmunol. 2017 Oct 15;311:71-78. doi: 10.1016/j.jneuroim.2017.08.005. Epub 2017 Aug 18.
Accumulating evidence shows that the immunoproteasome participates in the immune response, beyond its initial role in the protein degradation. Here, we tested the effects of the selective immunoproteasome inhibitor, ONX-0914, on experimental autoimmune myasthenia gravis (EAMG). We found that ONX-0914 ameliorated the severity of ongoing EAMG by reducing the autoantibody affinity, accompanied with decreased Tfh cells and antigen presenting cells. Also it reduced the percentage of Th17 cells and inhibited the secretion of IL-17. Our data indicated ONX-0914 may bring benefit for MG therapy.
越来越多的证据表明，免疫蛋白酶体除了在蛋白质降解中发挥初始作用外，还参与免疫反应。在此，我们测试了选择性免疫蛋白酶体抑制剂ONX-0914对实验性自身免疫性重症肌无力（EAMG）的影响。我们发现，ONX-0914通过降低自身抗体亲和力改善了正在进行的EAMG的严重程度，同时Tfh细胞和抗原呈递细胞减少。此外，它还降低了Th17细胞的百分比并抑制了IL-17的分泌。我们的数据表明，ONX-0914可能对重症肌无力治疗有益。
